Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A prospective, single site, single-arm pilot study of CPX-351 (Vyxeos) in individuals <22 years with secondary myeloid neoplasms

Alyssa Kennedy, Yonghui Ni, Stanley Pounds, Jatinder Lamba, Hiroto Inaba, Matthew Rees, Amr Qudeimat, Emily Montgomery, Raul Ribeiro, Marcin Wlodarski

Blood (2025) 146 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2025-2097

Published: 2025

Journal Articles

Transformer neural network using DNA methylation for sensitive and specific diagnosis of acute leukemia

Pedro V. B. Orsini, Francisco Marchi, Anna Lux, Laura F. Crosara, Jeffrey Rubnitz, Jeffery Klco, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 118.

https://doi.org/10.1182/blood-2025-118

Published: 2025

Journal Articles

A patient-derived CRISPR platform reveals selective dependencies in Acute Myeloid Leukemia

Aneesha Nath, Nam Nguyen, Abderrahmane Tagmount, Nathan Seligson, Christopher Vulpe, Vivek Shastri, Dina Khalaf, Christopher Cogle, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2025-3504

Published: 2025

Journal Articles

Novel AML specific splice junction evaluation identifies ubc and DMBT1 as top proteins of clinical and therapeutic relevance in pediatric Acute Myeloid Leukemia

Ryanne Mulligan, Alyssa Obermayer, Xiaotu Ma, Paulo Rodriguez, Stanley Pounds, Rhonda Ries, Soheil Meshinchi, Timothy Shaw, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2025-3497

Published: 2025

Journal Articles

Long-read whole genome sequencing improves clinical management in acute leukemia

Anna Lux, Francisco Marchi, Antonella Oettl, Petr Starostik, Dina Khalaf, Christopher Cogle, Stanley Pounds, Vivek Shastri, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 6110.

https://doi.org/10.1182/blood-2025-6110

Published: 2025

Journal Articles

GWAS-guided pharmacogenomic risk scores predict premedication-related pegaspargase hypersensitivity and toxicities in pediatric and adolescent young adults with acute lymphoblastic leukemia or lymphoma

Vivek Shastri, Sonia Morales, Anurag Agrawal, Christine Phillips, Keith August, Erin Guest, Carol Lin, Beth Apsel Winger, Catherine Aftandilian, Van Huynh, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 6881.

https://doi.org/10.1182/blood-2025-6881

Published: 2025

Journal Articles

Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML

Naifah Alshameri, Francisco Marchi, Soheil Meshinchi, Xueyuan Cao, Jeffrey Rubnitz, Raul Ribeiro, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 1712.

https://doi.org/10.1182/blood-2025-1712

Published: 2025

Journal Articles

Pharmacogenetic variants in UGT1A1/UGT1A3 and ABCC2 associate with deferasirox efficacy in transfusion-dependent thalassemia.

Chandni Patel, Vivek Shastri, Janel Long-Boyle, Johnny Li, Felicity Rose, Beth Apsel Winger, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 1140.

https://doi.org/10.1182/blood-2025-1140

Published: 2025

Journal Articles

Epigenetic priming improves survival for pediatric Acute Myeloid Leukemia: Results from the multicenter randomized AML16 trial

Blood (2025) 146 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2025-3446

Published: 2025

Journal Articles

A TFPI missense variant provides protection against severe febrile neutropenia in pediatric Acute Myeloid Leukemia

Satyavardhan Rao Nittu, Richard Marrero, Xueyuan Cao, Huiyun Wu, Raul Ribeiro, Jeffrey Rubnitz, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 7028.

https://doi.org/10.1182/blood-2025-7028

Published: 2025

Journal Articles

Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia

David Chen, Maria Baer, Sandrine Niyongere, Ashkan Emadi, Vivek Shastri, Jatinder Lamba, Michael Loken, Larissa Sanglard, Rena Lapidus, Soren Bentzen, Vu Duong

Blood (2025) 146 (Supplement 1): 999.

https://doi.org/10.1182/blood-2025-999

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Journal Articles

EV-mirnas predict outcomes in pediatric AML: A pilot study

Abdullah Alhumaid, Vivek Shastri, Zachary Greenberg, Jinmai Jiang, Raul Ribeiro, Jeffrey Rubnitz, Mei He, Thomas Schmittgen, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2025-3484

Published: 2025

Journal Articles

Proteomics reveals COX7B as a prognostically relevant oxphos-linked protein in pediatric AML

Ryanne Mulligan, Ya Huang, Xueyuan Cao, Junmin Peng, Raul Ribeiro, Jeffrey Rubnitz, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 5277.

https://doi.org/10.1182/blood-2025-5277

Published: 2025

Journal Articles

Identification of therapeutic vulnerabilities in FLT3-mutated AML through customized CRISPR screens

Phani Krishna Parcha, Nam Nguyen, Abderrahmane Tagmount, Christopher Vulpe, Stanley Pounds, Jatinder Lamba

Blood (2025) 146 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2025-3272

Published: 2025

Journal Articles

Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients

Bradley Stockard, PharmD, Joy Guingab, PhD, Timothy Garrett, PhD, Stanley Pounds, PhD, Jeffrey E Rubnitz, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 5105.

https://doi.org/10.1182/blood.V130.Suppl_1.5105.5105

Published: 2017

Journal Articles

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Jatinder Lamba, PhD, Lata Chauhan, PhD, Miyoung Shin, PhD, Michael R. Loken, PhD, Jessica A. Pollard, MD, Jim Wang, Richard Aplenc, MD, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Todd A Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 3826.

https://doi.org/10.1182/blood.V130.Suppl_1.3826.3826

Published: 2017

Journal Articles

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Lata Chauhan, PhD, Todd A Alonzo, PhD, Jim Wang, Michael R. Loken, PhD, Jessica A. Pollard, MD, Richard Aplenc, MD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Betsy A Hirsch, PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2526.

https://doi.org/10.1182/blood.V130.Suppl_1.2526.2526

Published: 2017

Journal Articles

CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates

Katherine Tarlock, MD, Jatinder Lamba, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2661.

https://doi.org/10.1182/blood.V130.Suppl_1.2661.2661

Published: 2017

Journal Articles

Risk Score Generated from Ara-C Metabolic Pathway Predicts Leukemic Cell Intracellular Ara-CTP Levels in AML-97 Pediatric Patients

Abdelrahman Elsayed, BSc, MSc, Kristine R Crews, PharmD, Xueyuan Cao, PhD, Jeffrey E Rubnitz, MD PhD, Stanley Pounds, PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2666.

https://doi.org/10.1182/blood.V130.Suppl_1.2666.2666

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A prospective, single site, single-arm pilot study of CPX-351 (Vyxeos) in individuals <22 years with secondary myeloid neoplasms

Transformer neural network using DNA methylation for sensitive and specific diagnosis of acute leukemia

A patient-derived CRISPR platform reveals selective dependencies in Acute Myeloid Leukemia

Novel AML specific splice junction evaluation identifies ubc and DMBT1 as top proteins of clinical and therapeutic relevance in pediatric Acute Myeloid Leukemia

Long-read whole genome sequencing improves clinical management in acute leukemia

GWAS-guided pharmacogenomic risk scores predict premedication-related pegaspargase hypersensitivity and toxicities in pediatric and adolescent young adults with acute lymphoblastic leukemia or lymphoma

Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML

Pharmacogenetic variants in UGT1A1/UGT1A3 and ABCC2 associate with deferasirox efficacy in transfusion-dependent thalassemia.

Epigenetic priming improves survival for pediatric Acute Myeloid Leukemia: Results from the multicenter randomized AML16 trial

A TFPI missense variant provides protection against severe febrile neutropenia in pediatric Acute Myeloid Leukemia

Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

EV-mirnas predict outcomes in pediatric AML: A pilot study

Proteomics reveals COX7B as a prognostically relevant oxphos-linked protein in pediatric AML

Identification of therapeutic vulnerabilities in FLT3-mutated AML through customized CRISPR screens

Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates

Risk Score Generated from Ara-C Metabolic Pathway Predicts Leukemic Cell Intracellular Ara-CTP Levels in AML-97 Pediatric Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only